RAJAFOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31

TFA Therapeutics, Inc.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on May 15, 2026

$9.18+0.00 (0.00%)

Close on Oct 16, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Dec 31, 2025

TFA Therapeutics reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in TFA Therapeutics's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in TFA Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is RAJAF.

Revenue growth-0.6% · median -21.7%

Gross margin61.1% · median 31.7%

Operating margin-11.3% · median -110.9%

Net margin-12.4% · median -150.4%

Company	Revenue	Growth
MEHA	$6.70M	+3.2%
RAJAF	$1.25M	-0.6%
CFOO	$185.87K	-46.6%
AKAN	–	–
ADIA	–	–
BON	–	–

Company

Exchange: OTC
Industry: Medicinal Chemicals & Botanical Products
Fiscal year ends: December 31
Employees: 16
Auditor: YCM CPA INC
SEC CIK: 1885680

Advertisement
300 × 250